This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

The hepatocyte growth factor (HGF) and its receptor, the transmembrane tyrosine kinase
cMET, promote cell proliferation, survival, motility, and invasion as well as morphogenic …

MET is a tyrosine kinase receptor that, upon binding of its natural ligand, the hepatocyte
growth factor (HGF), is phosphorylated and subsequently activates different signalling …

The hepatocyte growth factor and its receptor c-Met direct a pleiotropic signal transduction
pathway that controls cell survival. We previously demonstrated that mice lacking c-Met (Met …

Hepatocellular carcinoma (HCC) is a common type of cancer, with approximately 260,000
new cases each year, and liver cirrhosis is generally considered a major predisposing factor …

Bone marrow (BM) stromal cells, which include macrophages, fibroblasts, endothelial cells,
and adipocytes, have been shown to produce several factors that modulate the growth of BM …

Results Firstly, the serum HGF levels were significantly higher in invasive gross type or in IM-
positive tumors. Secondly, the mean expression value of HGF protein in tumors was 0.56+ …

Hepatocyte growth factor (HGF) and its receptor c-Met are involved in liver regeneration. The
role of HGF and c-Met in liver regeneration in rat following two-thirds partial hepatectomy …

Met tyrosine kinase receptor, also known as c-Met, is the HGF (hepatocyte growth factor)
receptor. The HGF/Met pathway has a prominent role in cardiovascular remodelling after …

Hepatocyte growth factor (HGF), a plasminogen-related growth factor, is the ligand for Met, a
receptor tyrosine kinase implicated in development, tissue regeneration, and invasive tumor …